Inhibition of microRNA-34a Enhances Survival of Human Bone Marrow Mesenchymal Stromal/Stem Cells Under Oxidative Stress

AEG 1,2,3,4 Yang Liu*
BCE 3,4 Xiaohu Zhang*
F 2 Jie Chen
DG 2 Tingyu Li

* Contributing equally as first author

Corresponding Authors: Yang Liu, e-mail: cyggly@126.com, Tingyu Li, e-mail: tyli@vip.sina.com

Source of support: This work was supported by the Natural Science Foundation Project of CQ CSCT (No. 2011BB5138) and the National Natural Science Foundation of China (No. 81100475 and 81271385)

Background: Mesenchymal stromal/stem cells (MSCs) are broadly used for many diseases, but the efficacy of MSC engraftment is very low due to low viability and high cell death rate under a stressful microenvironment. The present study aimed to investigate whether microRNA-34a (miR-34a), which is a downstream target of P53, is involved in H$_2$O$_2$-induced MSC cell death.

Material/Method: Human bone marrow MSCs (hMSCs) were purchased from Lonza and were cultured as previously described. hMSCs were transfected with miR-34a inhibitor and exposed to H$_2$O$_2$. Cell proliferation assay was used to assess the survival rate of hMSCs. Real-time PCR and Western blot analysis were used to examine proliferation and survival ability of hMSCs.

Results: H$_2$O$_2$ exposure significantly increased miR-34a expression in human bone marrow MSCs. H$_2$O$_2$ challenge induced massive MSC cell death along with reduction of expression of proliferation marker Ki67 and survival-related genes Bcl-2 and Survivin. Transfection of miR-34a inhibitor anti-34a led to a significant protective effect and rescued MSC cell death triggered by H$_2$O$_2$ exposure by 50%. Moreover, anti-34a dramatically increased Bcl-2 and Ki67 mRNA expression levels by over 10-fold compared to the mock control group under H$_2$O$_2$ exposure. The protein levels of Bcl-2 and Survivin were also rescued by anti-34a treatment by 50%.

Conclusions: Our results suggest that miR-34a plays a key role in oxidative stress-induced MSC cell death, and targeting miR-34a might be a promising strategy to enhance the survival rate of engrafted stem cells, which may improve therapeutic outcome.

MeSH Keywords: Cell Survival • Mesenchymal Stromal Cells • MicroRNAs • Oxidative Stress

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/904618

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background

Mesenchymal stromal/stem cells (MSCs) are a group of multipotent stromal cells with capacity of self-renewal and multilineage potential that can differentiate into osteoblasts, chondrocyte, myocytes, and adipocytes [1–3]. MSCs have been broadly used and proven safe and effective in clinical cell therapy trials for many diseases, such as stroke, neurodegenerative diseases, myocardial infarction, diabetes, and kidney injury [4–7]. There are also reports of adverse effect of MSC in clinical studies [8] and in clinical trials [9], suggesting MSCs must be used with extreme caution in clinical experiments and in clinical trials [8,10]. However, it is well accepted that the therapeutic outcomes of MSCs are attributed to direct cell differentiation and paracrine effects that promote endogenous tissue regeneration, anti-inflammation, and anti-apoptosis [11]. Although MSCs therapies have shown promising effectiveness, the efficacy of MSC transplantation is far from satisfactory due to low viability and high cell death rate of transplanted MSCs [12–14].

A highly stressful microenvironment is the main factor that induces apoptosis in engrafted MSCs [15,16]. In ischemia tissue (e.g., cardiac muscle or brain infarction), increased reactive oxygen species (ROS) induces massive cell death of donor MSCs and thus shortens its effective time to only a few days [6]. Prevention of MSC apoptosis from ROS challenge is urgently needed for improving the therapeutic outcome of MSCs therapy.

MicroRNAs (miRNAs) are small non-coding RNAs (approximately 22 nucleotides in length) which play vital roles in post-transcriptional regulation of gene expression. miRNAs can base-pair with complementary sequences with target mRNAs and silence the protein translation process by cleavage or destabilization of target mRNA and stop protein translation. Among the various miRNAs, miR-34a is a direct transcriptional target of p53 [17,18], which is considered as the gatekeeper protein that determines if a cell should undergo cell-cycle arrest, repair, or apoptosis under ROS and oxidative stress [19,20]. The p53 pathway is involved in MSC apoptosis, and platelet-derived growth factor treatment decreased the expression of p53 and protected MSCs from apoptosis under hypoxia condition [21,22]. p53 activation induces expression of miR-34a both in vivo and in vitro. In unrelated cell lines, such as cancer cell lines, inactivation of miR-34a strongly inhibits p53-mediated apoptosis in a cell stress condition, while overexpression of miR-34a increases apoptosis and cell-cycle arrest [23]. In our previous work, we demonstrated that miR-34a is involved in stem cell fate determination and regeneration in the nervous system [5]. We also found that miR-34a expression was negatively correlated with cell survival rate in rat bone marrow-derived dedifferentiated MSCs [5]. Emerging evidence indicates that miRNAs are actively involved in MSC differentiation [5,24], but there has been scant study of the role of miR-34a in the apoptosis of MSCs under stressful conditions.

In the present study, we sought to determine if miR-34a is involved in apoptosis of human bone marrow MSCs under oxidative stress induced by H2O2 and to provide a new target to improve MSC survival in cell therapies in multiple diseases.

Material and Methods

Cell culture

Human bone marrow MSCs were purchased from Lonza (Walkersville, MD, USA). These cells have been tested for MSC surface marker expression and multilineage differentiation ability. Briefly, cells were cultured in alpha-MEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C in a humidified 5% CO2 incubator, and media were changed every 2–3 days. After reaching to 70–80% confluence, cells were washed with phosphate-buffered saline (PBS), detached with 0.25% trypsin-EDTA (Invitrogen), then centrifuged and expanded at 1:3 split ratios.

Transfection of miR-34a inhibitor (anti-34a)

MSCs were transfected with anti-34a as previously described [5,4]. Briefly, MSCs were seeded at a density of 2×105 cells per well in 6-well plates in culture medium without antibiotics. Cells were transfected with 200 nM anti-34a and negative control (Ambion, USA) using Lipofectamine 2000 (Invitrogen) at 70% confluence following the manufacturer’s instructions. Transfection efficiency was determined by quantitative real-time PCR at day 1 and day 2 after transfection.

Detection of miR-34a expression

Total RNA was extracted using the mirVana miRNA isolation kit (Applied Biosystems/Ambion, Austin, TX) according to the manufacturer’s instructions. We converted 40 ng total RNA to cDNA using a TaqMan microRNA Reverse Transcription kit (Applied Biosystems) with specific primers for miR-34a and RNU48. Real-time PCR was carried out on the ABI 7500 real-time PCR machine (Applied Biosystems) in reaction volumes of 20 μl containing 10 μl TaqMan 2× Universal PCR Master Mix, no AmpErase UNG, 1 μl 20× TaqMan microRNA Assay Mix (Applied Biosystems) and 1.33 μl template cDNA. Thermal cycling conditions were 40 cycles at 95°C for 15 s and 60°C for 60 s. RNU48 was used as an endogenous control. Relative expression of miR-34a was calculated using the comparative delta-delta Ct value method.
Cell proliferation assay

Cell proliferation was determined using Cell Titer96® Aqueous cell proliferation assay (Promega, Madison, WI). Briefly, MSCs were seeded in triplicates in 96-well plates at a density of 1×10^3 cells/well in 100 μl full culture medium and transfected with anti-34a, as described above. One day post-transfection, cells were treated with 100 μM H_2O_2 for 1 h. Cells were incubated with 20 μl Cell Titer96 Aqueous One solution 24 h later, according to the manufacturer’s protocol. Viable cells were spectrophotometrically measured at a wavelength of 490 nm.

SYBR Green-based real-time PCR for other target genes

SYBR Green-based real-time PCR was employed to measure relative mRNA expression levels of Bcl-2, Survivin, and Ki-67. Total mRNA was extracted using Trizol (Invitrogen) according to the manufacturer's instructions and then quantified using a Nano-drop ND-2000 spectrophotometer. We reverse-transcribed 500 ng mRNA using the High-Capacity cDNA synthesis kit (Applied Biosystems). All qPCR was performed in triplicate using the SYBR Green PCR Master Mix kit (Life Technologies) on an ABI 7500 real-time PCR machine (Applied Biosystems) starting at a hold stage of 95°C for 10 min, and 40 cycles of denaturation at 95°C for 15 s, annealing/extension at 60°C for 60 s followed by disassociation melt curve analysis. Negative controls (no template) were also conducted in triplicate for all target genes. Beta-actin expression was used as an internal control. Relative mRNA levels were expressed as fold-change compared to untreated cells.

Western blot analysis

Cells were lysed in RIPA buffer (150 mM NaCl; 50 mM Tris-Cl, pH 8.0; 1% NP-40; 0.5%; DTT; 0.1% SDS), and total protein extracts were collected. Protein concentration was determined using bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL) and 30 μg of total protein was loaded into 10% SDS-PAGE gel. Following electrophoresis, proteins were transferred onto the nitrocellulose membranes (Millipore, USA). The membranes were blocked for non-specific binding with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) for 1 h at room temperature and then incubated with specific primary antibodies at 4°C overnight. After washing 3 times with TBST, membranes were incubated with HRP-conjugated secondary antibodies (Cell Signaling Technology, 1: 10 000) for 1 h at room temperature. Later, the signals were detected by chemiluminescence using ECL kit (Pierce, USA). Primary antibodies used in this study were: anti-Bcl-2 (Santa Cruz, 1: 200), anti-Survivin (Cell Signaling Technology, 1: 500), and anti-beta-Actin (Sigma, 1: 2000).

Immunostaining

Cells were cultured on chamber slides and treated with H_2O_2 (0, 50,100, 200, and 500 μM) for 1 h. Then, 24 h later, cells were fixed with 4% paraformaldehyde in PBS, blocked in 5% normal serum at room temperature for 1 h, followed with primary antibody for Ki-67 (Cell Signaling Technology) at 4°C overnight. Then, cells were washed with PBS and incubated with secondary antibodies (Alexa Fluor568 goat anti-rabbit IgG, Invitrogen). Samples were counterstained with DAPI (49,6-diamidino-2-phenylindole; Invitrogen), examined with an Olympus Eclipse 80i Upright Microscope, and photographed using a SPOT RT-S6 1.4MP Slider camera system (Diagnostic Instruments, Inc.).

Statistical analysis

The data were processed using Prism 5.0 software. Data are reported as means ±SEM if not indicated otherwise. Comparisons among values for all groups were performed by one-way ANOVA or Student’s t-test. A “P” value of less than 0.05 was considered statistically significant.

Results

H_2O_2 challenge increased miR-34a levels in MSCs

To determine whether oxidative stress can change miR-34a level in MSCs, we used 100 μM H_2O_2 to treat the cells for 1 h in normal culture conditions. Mild ROS is provided by 100 μM H_2O_2 and can directly produce free radicals, including hydroxyl radical, which induces DNA injury and membrane lipid per-oxidation [14,25]. After 1 h of H_2O_2 treatment, the expression level of miR-34a was dramatically increased compared to the control group, indicating that 100 μM H_2O_2 stimulation activates miR-34a expression in MSCs (Figure 1).

Anti-34a successfully reduced miR-34a level by 70% in MSCs

To determine if miR-34a can be down-regulated by anti-34a, 200 nM anti-34a were transfected into MSCs by using Lipofectamine 2000. After 24 h of transfection, the miR-34a level was significantly down-regulated by about 70% (Figure 2). This result indicates that the level of miR-34a in MSCs can be manipulated using anti-34a.

Anti-34a rescued H_2O_2-induced cell death in MSCs

We next performed cell proliferation assay to determine if H_2O_2-induced cell death of MSCs is mediated by miR-34a. First, we did a pre-test to verify that the effects of anti-34a still existed after 2 days of transfection followed by H_2O_2 exposure.
Anti-34a reduced miR-34a level by 50% at 48 h after transfection (Figure 3A). One day post-transfection, cells were treated with 100 μM H₂O₂ or vehicle for 1 h, and the number of viable cells was measured 24 h later. As shown in Figure 3B, H₂O₂ challenge significantly reduced the number of viable cells, and anti-34a partially rescued the effect of H₂O₂ challenge. * P<0.05; ** P<0.01.

Anti-34a rescued H₂O₂-induced cell death in MSCs. (A). miR-34a level was effectively suppressed by anti-34a under H₂O₂ stress. (B). H₂O₂ challenge significantly reduced the number of viable MSCs, and anti-34a partially rescued the effect of H₂O₂ challenge. * P<0.05; ** P<0.01.

Anti-34a rescued Bcl-2, Survivin, and Ki67 levels reduced by H₂O₂ exposure

To explore the underlying mechanism of the effect of anti-34a against oxidative stress induced by H₂O₂, we hypothesized that anti-34a modulates the balance between cell proliferation and cell death. It has been reported that H₂O₂ represses anti-apoptotic gene Bcl-2 expression in many cell lines [15,26]. Hence, we measured the mRNA levels of Bcl-2 and a proliferation marker Ki67 to see whether anti34a could rescue the down-regulation of Bcl-2 and Ki67 induced by H₂O₂ treatment. As shown in Figure 4A, H₂O₂ significantly reduced mRNA expression of Bcl-2 in MSCs. Anti-34a not only rescued Bcl-2 mRNA decrease, but, more interestingly, augmented Bcl-2 mRNA to...
Inhibition of miRNA-34a enhances survival...

© Med Sci Monit, 2018; 24: 264-271

Figure 4. Anti-34a protected MSCs against H$_2$O$_2$ by enhancing expression of Bcl-2, Survivin, and Ki67. (A). The mRNA levels of anti-apoptotic genes Bcl-2, Survivin, and proliferation marker Ki67 were significantly higher in MSCs transfected with anti-34a under H$_2$O$_2$ challenge. ** P<0.01; *** P<0.001. (B). Consistent with mRNA expression, Bcl-2 and Survivin protein levels were partially rescued by anti-34a. *** P<0.001.

Discussion

MSCs have been extensively used in clinical trials as stem cell therapy for a wide range of diseases in the past 10 years due to their clinical safety, multipotency, low immunogenicity, immunosuppressive properties, and production of cytokines and growth factors [11,27,28]. MSC based cell therapy has been proven effective in many diseases, including neurodegenerative disease [4], stroke [29], heart disease [7], and kidney injury [30]. Although significant progress has been made in MSC therapy, there are still several major hurdles limiting its widespread use. Low viability of transplanted MSCs is one of the major obstacles. ROS might play a crucial role in limiting the survival of engrafted MSCs. Increased ROS by ischemia induces neuronal or myocardial necrosis and infarction. Moreover, high levels of ROS in the ischemic tissue (i.e., brain or myocardium) are also harmful to the engrafted MSCs [31,32]. ROS accumulation is an important effector that activates the p53 pathway, which in turn induces cell apoptosis [19]. ROS inhibitor ameliorates senescence or apoptosis in cancer cells and stem cells [33–35]. These findings suggest that ROS is a priming effector that induces cell apoptosis, especially in ischemic tissue where ROS is highly elevated due to massive death cell. Therefore, the engrafted MSCs in the ischemic area thus might sustain oxidative stress from high levels of ROS in the microenvironment, resulting in MSC apoptosis and limitation of their therapeutic effect. Enhancing the survival of engrafted MSCs has been an attractive strategy to improve MSC therapeutic outcomes in the past few years. Several ex vivo genetic modification of MSCs targeting Bcl-2, TLR4, Survivin, and CCR1/CXCR2 has been proposed and proven effective in enhancing MSC survival [36]. Li et al. found that overexpression of Bcl-2 in MSCs reduced MSC apoptosis by 32% in vitro, and surviving MSCs were about 1–2 fold higher than that of control MSCs at different time points after cell transplantation in a rat myocardial infarction model [13]. We found that MSCs that have undergone a dedifferentiation-reprogramming improved cell survival...
Supplementary Figure 1. Immunostaining of Ki67 in MSCs after H₂O₂ treatment. After H₂O₂ treatment at different dosages (0, 50, 100, 200, and 500 μM), Ki67 expression was detected by immunostaining. Left lane: DAPI; middle lane: Ki67; right lane: the merged image of DAPI and Ki67.
in an \( \text{H}_2\text{O}_2 \) oxidative stress model and an in vivo rat hypoxia-ischemic brain damage model, and these improvements were partly attributed to increased Bcl-2 expression and decreased miR-34a in the dedifferentiation-reprogrammed MSCs [5].

Interestingly, a recent study showed hypoxia induced regulation of miR-34a in colorectal cancer cells, providing evidence of the link between miR-34 and ROS [37]. In the present study, we first confirmed that the miR-34a level in MSCs was significantly increased under mild \( \text{H}_2\text{O}_2 \)-mediated oxidative stress. Anti-34a successfully repressed miR-34a expression in MSCs under control conditions. These data indicate that miR-34a is constantly expressed in MSCs, consistent with another report that miR-34a is functionally expressed in mouse neural stem cells [24]. \( \text{H}_2\text{O}_2 \) induced massive MSCs cell death, and pre-transfection of anti-34a could partially rescue cell death induced by \( \text{H}_2\text{O}_2 \). Bcl-2 is a 26-kDa anti-apoptotic protein serving as a critical regulator of the apoptotic pathway to inhibit cell death [38]. Several lines of evidence indicate that miR-34a directly targets Bcl-2 mRNA and represses its expression [39]. Consistent with previous findings, we found that \( \text{H}_2\text{O}_2 \) treatment severely reduced Bcl-2 mRNA and protein levels in MSCs. Pre-transfection of anti-34a into MSCs dramatically increased Bcl-2 mRNA level and partially restored its protein level. The proliferation marker Ki67 showed a similar trend as that of Bcl-2. Most interestingly, anti-34a treatment not only restored the mRNA level of Bcl-2 and Ki67, but achieved even higher levels than that of the control group. This finding indicates that miR-34a is constantly expressed in MSCs and is functionally involved in the regulation of cell proliferation and cell death.

**Conclusions**

In summary, our study revealed that miR-34a plays a key role in ROS-induced MSC apoptosis. Repressing miR-34a expression by transfection of anti-34a increased MSC survival under oxidative stress. These findings offer a new insight into the importance of miR-34a in MSC apoptosis and suggest that manipulation of miR-34a expression may be a promising strategy to improve survival of transplanted MSCs in clinical stem cell therapies.

**Competing interests**

The authors have no conflict of interest to disclose.

**References:**

1. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 1997; 276: 71–74
2. Pittenger MF, Mackay AM, Beck SC et al: Multilineage potential of adult human mesenchymal stem cells. Science, 1999; 284: 143–47
3. Jiang Y, Jahagirdar BN, Reinhardt RL et al: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 2002; 418: 41–49
4. Joyce N, Annett G, Wirthlin L et al: Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med, 2010; 5: 933–46
5. Liu Y, Jiang X, Zhang X et al: Dedifferentiation-reprogrammed mesenchymal stem cells with improved therapeutic potential. Stem Cells, 2011; 29: 2077–89
6. Wen Z, Zheng S, Zhou C et al: Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med, 2011; 15: 1032–43
7. Wen Z, Zheng S, Zhou C et al: Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators. J Cell Mol Med, 2012; 16: 657–71
8. Ning H, Yang F, Jiang M et al: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia, 2008; 22: 593–99
9. Kurian AE, Albini TA, Townsend HJ et al: Vision loss after intravitreal injection of autologous "stem cells" for AMD. New Engl J Med, 2017; 376: 1047–53
10. Ankrum J, Karp JM: Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med, 2010; 16: 203–09
11. Yagi H, Soto-Gutierrez A, Parekkadan B et al: Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant, 2010; 19: 667–79
12. Song H, Kwon K, Lim S et al: Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells, 2005; 19: 402–07
13. Li W, Ma N, Ong L-L et al: Bcl-2 Engineered MSCs inhibited apoptosis and improved heart function. Stem Cells, 2007; 25: 2118–27
14. Zeng W, Xiao J, Zheng G et al: Antioxidant treatment enhances human mesenchymal stem cell anti-stress ability and therapeutic efficacy in an acute liver failure model. Sci Rep, 2015; 5: 11100
15. Mohammadzadeh M, Halabian R, Gharahbaghian A et al: Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apopto
sis and cytotoxicity. Cell Stress Chaperones, 2012; 17: 553–65
16. Trouche E, Mias C, Seguelas MH et al: Characterization of monoamine oxidases in mesenchymal stem cells: Role in hydrogen peroxide generation and serotonin-dependent apoptosis. Stem Cells Dev, 2010; 19: 1571–78
17. Tarasov V, Jung P, Verdoott B et al: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 2007; 6: 1586–93
18. Liao JM, Cao B, Zhou X et al: New insights into p53 functions through its target microRNAs. J Mol Cell Biol, 2014; 6: 206–17
19. Macip S, Igarashi M, Berggren P et al: Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol, 2003; 23: 8576–85
20. Karawajew L, Rhein P, Czerwony G et al: Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species. Blood, 2005; 105: 4767–75
21. Lv B, Li F, Fang J et al: Hypoxia inducible factor 1alpha promotes survival of mesenchymal stem cells under hypoxia. Am J Transl Res, 2017; 9: 1521–29
22. Zhang JM, Feng FE, Wang QM et al: Platelet-derived growth factor-BB promotes mesenchymal stem cells (MSCs) derived from immune thrombocytopenia patients against apoptosis and senescence and maintains MSC-mediated immunosuppression. Stem Cells Transl Med, 2016; 5: 1631–43
23. Raver-Shapira N, Marciano E, Meiri E et al: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell, 2007; 26: 733–43
24. Aranha MM, Santos DM, Sola S et al: miR-34a regulates mouse neural stem cell differentiation. PLoS One, 2011; 6: e21396
25. Konat GW: \( \text{H}_2\text{O}_2 \)-induced higher order chromatin degradation: A novel mechanism of oxidative genotoxicity. J Biosci, 2003; 28: 57–60
26. Valls DM, Kemp TJ, Clerk A: Regulation of Bcl-2L expression by \( \text{H}_2\text{O}_2 \) in cardiac myocytes. J Biol Chem, 2003; 278: 25542–47

© Med Sci Monit, 2018; 24: 264-271
27. Mohammadian M, Shamsasenjan K, Lotfi Nezhad P et al: Mesenchymal stem cells: New aspect in cell-based regenerative therapy. Adv Pharm Bull, 2013; 3: 433–37

28. Wei X, Yang X, Han ZP et al. Mesenchymal stem cells: A new trend for cell therapy. Acta Pharmacol Sin, 2013; 34: 747–54

29. Diez-Tejedor E, Gutierrez-Fernandez M, Martinez-Sanchez P et al: Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: A safety assessment. A phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. J Stroke Cerebrovasc Dis, 2014; 23(10): 2694–700

30. Humphreys BD, Bonventre JV: Mesenchymal stem cells in acute kidney injury. Annu Rev Med, 2008; 59: 311–25

31. Levraut J, Iwase H, Shao ZH et al: Cell death during ischemia: Relationship to mitochondrial depolarization and ROS generation. Am J Physiol Heart Circ Physiol, 2003; 284: H549–58

32. Carpi A, Menabo R, Kaluderovic N et al. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta, 2009; 1787: 774–80

33. Chen T, Wong YS: Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci, 2008; 65: 2763–75

34. Nguyen Ngoc TD, Son YO, Lim SS et al. Sodium fluoride induces apoptosis in mouse embryonic stem cells through ROS-dependent and caspase- and JNK-mediated pathways. Toxicol Appl Pharmacol, 2012; 259: 329–37

35. Yuan L, Wei S, Wang J et al: Isoorientin induces apoptosis and autophagy simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 signaling pathways in HepG2 cancer cells. J Agric Food Chem, 2014; 62: 5390–400

36. Lee S, Choi E, Cha M-J et al: Cell adhesion and long-term survival of transplanted mesenchymal stem cells: A prerequisite for cell therapy. Oxid Med Cell Longev, 2015; 2015: 9

37. Li H, Rokavec M, Jiang L et al. Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells. Gastroenterology, 2017 [Epub ahead of print]

38. Reed JC: Bcl-2 family proteins. Oncogene, 1998; 17: 3225–36

39. Chen H, Wang J, Hu B et al: miR-34a promotes Fas-mediated cartilage end-plate chondrocyte apoptosis by targeting Bcl-2. Mol Cell Biochem, 2015; 406: 21–30